Skip to main content Accessibility help
×
Home
  • Print publication year: 2011
  • Online publication date: August 2011

26 - Neuroacanthocytosis

References

1. Rampoldi L, Dobson-Stone C, Rubio JP et al. A conserved sorting-associated protein is mutant in chorea-acanthocytosis. Nat Genet 2001; 28: 119–20.
2. Ueno S, Maruki Y, Nakamura M et al. The gene encoding a newly discovered protein, chorein, is mutated in chorea-acanthocytosis. Nat Genet 2001; 28: 121–2.
3. Dobson-Stone C, Danek A, Rampoldi L et al. Mutational spectrum of the CHAC gene in patients with chorea-acanthocytosis. Eur J Hum Genet 2002; 10: 773–81.
4. Ho M, Chelly J, Carter N et al. Isolation of the gene for McLeod syndrome that encodes a novel membrane transport protein. Cell 1994; 77: 869–80.
5. Levine IM. An hereditary neurologic disease with acanthocytosis. Neurology 1964; 14: 272.
6. Critchley EM, Clark DB, Wikler A. Acanthocytosis and neurological disorder without betalipoproteinemia. Arch Neurol 1968; 18: 134–40.
7. Critchley EM, Nicholson JT, Betts JJ et al. Acanthocytosis, normolipoproteinaemia and multiple tics. Postgrad Med J 1970; 46: 698–701.
8. Velayos-Baeza A, Holinski-Feder E, Nietzel B. Chorea-acanthocytosis genotype in Critchley’s original Kentucky neuroacanthocytosis kindred. Arch Neurol in press.
9. Hardie RJ, Pullon HW, Harding AE et al. Neuroacanthocytosis. A clinical, haematological and pathological study of 19 cases. Brain 1991; 114: 13–49.
10. Gandhi S, Hardie RJ, Lees AJ. An update on the Hardie neuroacanthocytosis series. In: Walker RH, Saiki S, Danek A, eds. Neuroacanthocytosis Syndromes II. Berlin, Heidelberg: Springer-Verlag; 2008: 43–51.
11. Hayflick SJ, Westaway SK, Levinson B et al. Genetic, clinical, and radiographic delineation of Hallervorden–Spatz syndrome. N Engl J Med 2003; 348: 33–40.
12. Walker RH, Rasmussen A, Rudnicki D et al. Huntington’s disease-like 2 can present as chorea-acanthocytosis. Neurology 2003; 61: 1002–4.
13. Tschopp L, Raina G, Salazar Z et al. Neuroacanthocytosis and carbamazepine responsive paroxysmal dyskinesias. Parkinsonism Relat Disord 2008; 14: 440–2.
14. Mukoyama M, Kazui H, Sunohara N et al. Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes with acanthocytosis: a clinicopathological study of a unique case. J Neurol 1986; 233: 228–32.
15. Al-Asmi A, Jansen AC, Badhwar A et al. Familial temporal lobe epilepsy as a presenting feature of choreoacanthocytosis. Epilepsia 2005; 46: 1256–63.
16. Dobson-Stone C, Velayos-Baeza A, Jansen A et al. Identification of a VPS13A founder mutation in French Canadian families with chorea-acanthocytosis. Neurogenetics 2005; 6: 151–8.
17. Rampoldi L, Danek A, Monaco AP. Clinical features and molecular bases of neuroacanthocytosis. J Mol Med 2002; 80: 475–91.
18. Lossos A, Dobson-Stone C, Monaco AP et al. Early clinical heterogeneity in choreoacanthocytosis. Arch Neurol 2005; 62: 611–14.
19. Walker RH, Jung HH, Dobson-Stone C et al. Neurologic phenotypes associated with acanthocytosis. Neurology 2007; 68: 92–8.
20. Walterfang M, Yucel M, Walker R et al. Adolescent obsessive compulsive disorder heralding chorea-acanthocytosis. Mov Disord 2008; 23: 422–5.
21. Scheid R, Bader B, Ott DV et al. Development of mesial temporal lobe epilepsy in chorea-acanthocytosis. Neurology 2009; 73: 1419–22.
22. Saiki S, Hirose G, Sakai K et al. Chorea-acanthocytosis associated with Tourettism. Mov Disord 2004; 19: 833–6.
23. Bader B, Walker RH, Vogel M et al. Tongue protrusion and feeding dystonia: a hallmark of chorea-acanthocytosis. Mov Disord 2010; 25(1): 127–9.
24. Walker RH, Liu Q, Ichiba M et al. Self-mutilation in chorea-acanthocytosis: manifestation of movement disorder or psychopathology? Mov Disord 2006; 21: 2268–9.
25. Hewer E, Danek A, Schoser BG et al. McLeod myopathy revisited: more neurogenic and less benign. Brain 2007; 130: 3285–96.
26. Jung HH, Brandner S. Malignant McLeod myopathy. Muscle Nerve 2002; 26: 424–7.
27. Danek A, Rubio JP, Rampoldi L et al. McLeod neuroacanthocytosis: genotype and phenotype. Ann Neurol 2001; 50: 755–64.
28. Oechslin E, Kaup D, Jenni R et al. Cardiac abnormalities in McLeod syndrome. Int J Cardiol 2009; 132: 130–2.
29. Storch A, Kornhass M, Schwarz J. Testing for acanthocytosis: a prospective reader-blinded study in movement disorder patients. J Neurol 2005; 252: 84–90.
30. Sorrentino G, De Renzo A, Miniello S et al. Late appearance of acanthocytes during the course of chorea-acanthocytosis. J Neurol Sci 1999; 163: 175–8.
31. Dobson-Stone C, Velayos-Baeza A, Filippone LA et al. Chorein detection for the diagnosis of chorea-acanthocytosis. Ann Neurol 2004; 56: 299–302.
32. Allen FH, Krabbe SM, Corcoran PA. A new phenotype (McLeod) in the Kell blood-group system. Vox Sang 1961; 6: 555–60.
33. Redman CM, Russo D, Lee S. Kell, Kx and the McLeod syndrome. Baillières Best Pract Res Clin Haematol 1999; 12: 621–35.
34. Henkel K, Danek A, Grafman J et al. Head of the caudate nucleus is most vulnerable in chorea-acanthocytosis: a voxel-based morphometry study. Mov Disord 2006; 21: 1728–31.
35. Saiki S, Sakai K, Kitagawa Y et al. Mutation in the CHAC gene in a family of autosomal dominant chorea-acanthocytosis. Neurology 2003; 61: 1614–16.
36. Bader B, Arzberger T, Heinsen H et al. Neuropathology of chorea-acanthocytosis. In: Walker RH, Saiki S, Danek A, eds. Neuroacanthocytosis Syndromes II. Berlin, Heidelberg: Springer-Verlag; 2008: 187–95.
37. Lee S, Sha Q, Wu X et al. Expression Profiles of Mouse Kell, XK, and XPLAC mRNA. J Histochem Cytochem 2007; 55: 365–74.
38. Claperon A, Hattab C, Armand V et al. The Kell and XK proteins of the Kell blood group are not co-expressed in the central nervous system. Brain Res 2007; 1147: 12–24.
39. Walker RH, Danek A, Uttner I et al. McLeod phenotype without the McLeod syndrome. Transfusion 2006; 47: 299–305.
40. Walker RH, Jung HH, Tison F et al. Phenotypic variation among brothers with the McLeod neuroacanthocytosis syndrome. Mov Disord 2007; 22: 244–8.
41. Jung HH, Hergersberg M, Kneifel S et al. McLeod syndrome: a novel mutation, predominant psychiatric manifestations, and distinct striatal imaging findings. Ann Neurol 2001; 49: 384–92.
42. Alonso ME, Teixeira F, Jimenez G et al. Chorea-acanthocytosis: report of a family and neuropathological study of two cases. Can J Neurol Sci 1989; 16: 426–31.
43. Vital A, Bouillot S, Burbaud P et al. Chorea-acanthocytosis: neuropathology of brain and peripheral nerve. Clin Neuropathol 2002; 21: 77–81.
44. Brin MF, Hays A, Symmans WA et al. Neuropathology of McLeod phenotype is like chorea-acanthocytosis (CA). Can J Neurol Sci 1993; 20(Suppl 4): 234.
45. Rinne JO, Daniel SE, Scaravilli F et al. Nigral degeneration in neuroacanthocytosis. Neurology 1994; 44: 1629–32.
46. Geser F, Tolnay M, Jung HH. The Neuropathology of McLeod Syndrome. In: Walker RH, Saiki S, Danek A, eds. Neuroacanthocytosis Syndromes II. Berlin, Heidelberg: Springer-Verlag; 2008: 197–203.
47. McIntosh J. Multidisciplinary neurorehabilitation in chorea-acanthocytosis; A case study. In: Walker RH, Saiki S, Danek A, editors. Neuroacanthocytosis Syndromes II. Berlin Heidelberg, Germany, Springer-Verlag. 2008; 271–284.
48. Fontenelle LF, Leite MA. Treatment-resistant self-mutilation, tics, and obsessive-compulsive disorder in neuroacanthocytosis: a mouth guard as a therapeutic approach. J Clin Psychiatry 2008; 69: 1186–7.
49. Burbaud P, Rougier A, Ferrer X et al. Improvement of severe trunk spasms by bilateral high-frequency stimulation of the motor thalamus in a patient with chorea-acanthocytosis. Mov Disord 2002; 17: 204–7.
50. Wihl G, Volkmann J, Allert N et al. Deep brain stimulation of the internal pallidum did not improve chorea in a patient with neuro-acanthocytosis. Mov Disord 2001; 16: 572–5.
51. Burbaud P. Deep brain stimulation in neuroacanthocytosis. Mov Disord 2005; 20: 1681–2.